Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507527-28-00

Acronym

Candi5V01

Enrollment

251

Registered

2023-11-21

Start date

2024-09-16

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent vulvovaginal candidiasis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Belgium, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026